The novel mechanism of action of the sodium-glucose co-transporter 2 inhibitor class played a major role in the design of clinical trials for Johnson & Johnson’s Invokana;putting the mechanism first and foremost helped with regulatory issues as well as emphasizing the differentiation needed for the commercial sphere.
FDA review documents for Invokana show how the trials were designed to provide a complex set of analyses to explore theoretical risks and benefits suggested by the unfamiliar mechanism of...
Read the full article – start your free trial today!
Join thousands of industry professionals who rely on Pink Sheet for daily insights
- Start your 7-day free trial
- Explore trusted news, analysis, and insights
- Access comprehensive global coverage
- Enjoy instant access – no credit card required
Already a subscriber?